Overview

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
Denovo Biopharma LLC
Eli Lilly and Company
Treatments:
Olanzapine